Ohio State hematologist Dr. Kerry Rogers says chemotherapy and newer targeted drugs both work well, and the right choice depends on the patient.
News|Articles|January 4, 2021
7 Ovarian Cancer News and Updates That Patients May Have Missed in 2020
Author(s)CURE staff
A roundup of some ovarian cancer news and updates that occurred in 2020 that patients may have missed.
Advertisement
There were several updates in the field of ovarian cancer in 2020. CURE® looks back at some of the news and updates in the field of ovarian cancer that patients may have missed.
- The Food and Drug Administration’s (FDA) approval of Zejula (niraparib) in May for the frontline maintenance treatment of adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy was exciting news for patients, according to a gynecologic oncology expert.
READ MORE . - Data published in JAMA Oncology demonstrated that regardless of length of breastfeeding, women who breastfeed are at significantly lower risk of ovarian cancer.
READ MORE .
- In an episode of the “CURE Talks Cancer” podcast, we spoke with a cervical cancer survivor — currently living with ovarian cancer — about a cross-country journey she took on a teal and white Harley Davidson motorcycle in the summer of 2019 to raise awareness for ovarian cancer.
LISTEN HERE . - Data from a case-controlled analysis of health insurance claims from a five-year period demonstrated that certain recurring symptoms appear to be associated with an ovarian cancer diagnosis, indicating that symptom awareness is relevant to identifying a disease that is typically diagnosed at a later stage.
READ MORE . - Most premenopausal women planning preventive surgery because of a predisposition to ovarian cancer would prefer to remove only their fallopian tubes, putting off removal of their ovaries until they reach menopause, recent study results demonstrated.
READ MORE . - There was not a statistically significant association between the use of powder in the genital area and risk for ovarian cancer, according to data published in JAMA Network.
READ MORE . - Treatment with Keytruda (pembrolizumab), Avastin (bevacizumab) and cyclophosphamide in patients with recurrent ovarian cancer was well tolerated and demonstrated clinical benefit in most patients, according to results from a trial published in JAMA Oncology.
READ MORE .
For more news on cancer updates, research and education, don’t forget to
Advertisement
Related to this article
Given an 18-month prognosis for peritoneal mesothelioma in 2007, a mother shares the joy of tapping her son out at his Air Force basic training graduation.
A once-daily oral pill gives patients with symptomatic TGCT another option when surgery could cause more harm than good.
For World NET Cancer Day, CURE answers seven common questions about neuroendocrine tumors, from carcinoid syndrome and Ki-67 to dotatate PET scans and treatment options.
Up to 40% of patients with classic hairy cell leukemia relapse within 10 to 15 years. An NIH researcher explains how adding Rituxan up front may help.
Gita Kwatra, PharmD, MBA, co-founder and CEO of the Glioblastoma Foundation, explains what happens to tumor tissue after brain surgery and how patients can ask their care team for genomic testing.
Most people with pancreatic cancer lose weight they didn't mean to. Here is how weight loss from poor digestion differs from cachexia, and what enzymes, eating strategies and appetite medicines can do.
Dr. Rebecca Dent explains how Datroway kept brain metastases in check longer than chemotherapy in triple-negative breast cancer, and what patients should know.
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumor
2
Neuroendocrine Tumors: 7 Questions Patients Ask, Answered
3
Datroway Slows Brain Metastases in Triple-Negative Breast Cancer
4
Why Rituxan Plus Cladribine May Delay Hairy Cell Leukemia Relapse
5